Equity Profile

CGON

CG Oncology, Inc.

Health CareBiotechnology$5.5B

Aug7Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely scrutinize this quarter.

N/A

Revenue Growth

Investors will look for any signs of revenue growth as it reflects the company's ability to expand its market presence and sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. With a market cap of $5 billion, it operates in the health care sector, which is increasingly important as demand for effective cancer therapies continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In the last quarter, CG Oncology reported an EPS of -$0.71, which was worse than the expected -$0.58, leading to a 0.64% increase in stock price the following day. The company continues to face challenges in meeting earnings expectations.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiencies.
Plans to enhance investor communication regarding upcoming milestones.

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has struggled to meet earnings estimates in recent quarters, leading to uncertainty among investors. The stock's implied volatility suggests that the market anticipates significant movement following the earnings report.

Bull Case

If CG Oncology can demonstrate progress in clinical trials and report better-than-expected EPS, it could restore investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to show any meaningful progress or continues to miss earnings expectations, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and their expected timelines?

The outcome of these trials can significantly influence the company's future revenue potential and investor confidence.

Will the company provide any guidance on revenue expectations for the upcoming quarters?

Clear guidance on revenue can help investors gauge the company's growth trajectory and financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of recent clinical trial advancements that could lead to a faster-than-expected revenue ramp-up.

Supporting Evidence

Options are pricing a 36.98% move, indicating high uncertainty that may not align with the company's actual performance.

The company's recent insider selling could suggest a strategic repositioning rather than a lack of confidence in future growth.

Key Risk

If the company provides strong clinical trial results, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn clinical advancements into financial results.

Bull Confirmed If

A positive update on clinical trials leading to a projected revenue increase of at least 20% year-over-year.

Bear Confirmed If

Continued losses with an EPS worse than -$0.71 and no clear path to profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±36.98%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.9%, with a raw directional average of -1.6% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.1M

15,600 sh

1 insider

Net

$1.1M

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests a potential stock increase of around 0.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess their positions.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.79%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress and results of key clinical trials.
2Any guidance on expected revenue growth for the next quarter.
3Insights into operational efficiencies and cost management.
4Details on partnerships or collaborations that may enhance product development.
5Management's outlook on market conditions and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

BP p.l.c.

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely scrutinize this quarter.

N/A

Revenue Growth

Investors will look for any signs of revenue growth as it reflects the company's ability to expand its market presence and sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiencies.
Plans to enhance investor communication regarding upcoming milestones.

Expectations

Wall Street Expectations

Bull Case

If CG Oncology can demonstrate progress in clinical trials and report better-than-expected EPS, it could restore investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to show any meaningful progress or continues to miss earnings expectations, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and their expected timelines?

The outcome of these trials can significantly influence the company's future revenue potential and investor confidence.

Will the company provide any guidance on revenue expectations for the upcoming quarters?

Clear guidance on revenue can help investors gauge the company's growth trajectory and financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of recent clinical trial advancements that could lead to a faster-than-expected revenue ramp-up.

Supporting Evidence

Options are pricing a 36.98% move, indicating high uncertainty that may not align with the company's actual performance.

The company's recent insider selling could suggest a strategic repositioning rather than a lack of confidence in future growth.

Key Risk

If the company provides strong clinical trial results, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn clinical advancements into financial results.

Bull Confirmed If

A positive update on clinical trials leading to a projected revenue increase of at least 20% year-over-year.

Bear Confirmed If

Continued losses with an EPS worse than -$0.71 and no clear path to profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±36.98%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.1M

15,600 sh

1 insider

Net

$1.1M

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests a potential stock increase of around 0.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess their positions.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.79%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress and results of key clinical trials.
2Any guidance on expected revenue growth for the next quarter.
3Insights into operational efficiencies and cost management.
4Details on partnerships or collaborations that may enhance product development.
5Management's outlook on market conditions and competitive landscape.